Rapid Medical’s DISTALS trial signals a structural shift in how medium vessel stroke may finally be treated
Rapid Medical disclosed late-breaking results from its DISTALS randomized controlled trial showing that the TIGERTRIEVER 13 thrombectomy device achieved significantly higher tissue reperfusion without symptomatic intracranial hemorrhage compared with medical management in medium vessel occlusion stroke. The data were presented at the 2026 International Stroke Conference and form the basis for a planned United States […]